Jounce Therapeutics, Inc. engages in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers. Its immunotherapies are designed to harness the patient's immune system to seek out and attack cancerous cells and tumors. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.
1030 Massachusetts Avenue
Cambridge, MA 02138
Founded in 2012
Jounce Therapeutics Appoints Duncan Higgons to its Board of Directors
Nov 17 15
Jounce Therapeutics, Inc. announced Duncan Higgons has been appointed to the company’s board of directors. Mr. Higgons has served as the chief operating officer at Agios Pharmaceuticals since 2009.
Jounce Therapeutics, Inc. Appoints Elizabeth Trehu as Chief Medical Officer
Nov 3 15
Jounce Therapeutics, Inc. announced the appointment of Elizabeth Trehu, M.D., to the position of chief medical officer. Dr. Trehu brings to Jounce more than 25 years of clinical experience, including nearly 15 years in the biotech industry leading translational and integrated hematology and oncology drug development. Dr. Trehu joins the company from Promedior, Inc., where she served as the chief medical officer. In this role, she was responsible for clinical development, clinical operations, regulatory affairs, quality assurance and program management, and led the creation and mplementation of clinical development plans for Promedior’s lead product candidate. Prior to Promedior, Dr. Trehu served as vice president, oncology product development and medical affairs for Infinity Pharmaceuticals, and earlier held various leadership positions at Genzyme Corporation, including vice president and general manager of hematology for Genzyme’s transplant oncology group. Earlier in her career, Dr. Trehu held roles of increasing responsibility at Millennium Pharmaceuticals, including vice president, oncology global medical affairs, and was integral in the development and commercialization of VELCADE. As an assistant professor of medicine at Tufts University School of Medicine, Dr. Trehu conducted preclinical and clinical research in immunotherapy with the NCI Cytokine Working Group.
Jounce Therapeutics, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 01:30 PM
Sep 25 15
Jounce Therapeutics, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 01:30 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Richard Murray, Chief Executive Officer.